Alliance Global Lowers Pluristem Therapeutics' Price Target to $4 From $9.50, Maintains Buy Rating
MT NewswiresJul 20, 2022 11:15 ET
Pluristem Therapeutics Price Target Cut to $4.00/Share From $9.50 by Alliance Global Partners
Dow JonesJul 20, 2022 09:31 ET
Pluristem Therapeutics Is Maintained at Buy by Alliance Global Partners
Dow JonesJul 20, 2022 09:31 ET
Pluristem Therapeutics analyst ratings
Benzinga Analyst RatingsJul 20, 2022 09:24 ET
Alliance Global Partners Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $4
Benzinga Real-time NewsJul 20, 2022 09:24 ET
No Data
No Data